{"id":"piperacillin-tazobactam-drug-combination","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Allergic reactions"},{"rate":null,"effect":"Clostridium difficile-associated diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piperacillin is a broad-spectrum beta-lactam antibiotic that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking. Tazobactam is a beta-lactamase inhibitor that irreversibly binds and inactivates beta-lactamase enzymes produced by resistant bacteria, preventing degradation of piperacillin and extending its spectrum of activity against otherwise resistant gram-negative and gram-positive organisms.","oneSentence":"Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing piperacillin to kill a broader spectrum of bacteria including beta-lactamase-producing organisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:26.792Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections in pediatric patients (including intra-abdominal, skin and soft tissue, and respiratory tract infections)"},{"name":"Febrile neutropenia in pediatric cancer patients"}]},"trialDetails":[{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT07484633","phase":"PHASE4","title":"A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","startDate":"2026-04","conditions":"Infection, Sepsis, NICU","enrollment":110},{"nctId":"NCT07481539","phase":"PHASE2","title":"Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment","status":"RECRUITING","sponsor":"Azienda Sanitaria Universitaria Friuli Centrale","startDate":"2026-03-24","conditions":"Bacteria Infection, Piperacillin, Tazobactam Drug Combination","enrollment":240},{"nctId":"NCT04692181","phase":"PHASE1, PHASE2","title":"SYN-004 Safety and Tolerability in Allo-HCT Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theriva Biologics, Inc.","startDate":"2021-02-15","conditions":"Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics","enrollment":36},{"nctId":"NCT06690905","phase":"PHASE4","title":"Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity","status":"COMPLETED","sponsor":"CR-CSSS Champlain-Charles-Le Moyne","startDate":"2025-02-26","conditions":"Infections, Obesity and Obesity-related Medical Conditions","enrollment":45},{"nctId":"NCT06712641","phase":"PHASE4","title":"Aminoglycosides in Early Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2026-04","conditions":"Sepsis","enrollment":1900},{"nctId":"NCT06080698","phase":"NA","title":"Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-02-22","conditions":"Gram-negative Bacteremia","enrollment":1030},{"nctId":"NCT03078010","phase":"PHASE2","title":"Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-10","conditions":"Intestinal Microbiome, Febrile Neutropenia","enrollment":347},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":146},{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":"Acute Kidney Injury","enrollment":750},{"nctId":"NCT06002607","phase":"","title":"Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2023-12-28","conditions":"Necrotizing Soft Tissue Infection","enrollment":50},{"nctId":"NCT06123169","phase":"PHASE3","title":"Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-04","conditions":"Pancreaticoduodenectomy, Antibiotherapy","enrollment":326},{"nctId":"NCT04986254","phase":"","title":"PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2019-10-17","conditions":"Pneumonia","enrollment":179},{"nctId":"NCT07352605","phase":"NA","title":"Percutaneous Drainage Versus Antibiotic Therapy for Acute Diverticulitis With Abscess.","status":"NOT_YET_RECRUITING","sponsor":"Azienda Sanitaria di Firenze","startDate":"2026-04","conditions":"Diverticular Disease of Colon","enrollment":50},{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":"Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam","enrollment":300},{"nctId":"NCT07318584","phase":"PHASE2","title":"Cefotetan Therapy for Escherichia Coli Infections","status":"NOT_YET_RECRUITING","sponsor":"Oregon Health and Science University","startDate":"2026-03","conditions":"E Coli Infection, ESBL Producing E.Coli","enrollment":84},{"nctId":"NCT07084428","phase":"","title":"Pancreatic Antibiotic Concentration Evaluation Assessment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brno University Hospital","startDate":"2024-01-15","conditions":"Acute Pancreatic Fluid Collection, Acute Pancreatitis","enrollment":40},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT05730257","phase":"NA","title":"Study Investigating Whether Robot-assisted Surgery Can Reduce Surgical Complications Following Kidney Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2023-05-08","conditions":"End Stage Renal Disease, Kidney Transplant; Complications","enrollment":106},{"nctId":"NCT02473263","phase":"PHASE3","title":"Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-09","conditions":"Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit","enrollment":398},{"nctId":"NCT01543334","phase":"","title":"Antibiotic Concentrations Among Critically Ill Patients","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2012-03","conditions":"Administration of Antibiotics in Intensive Care Units","enrollment":98},{"nctId":"NCT03269994","phase":"PHASE3","title":"Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-21","conditions":"Pancreatic Cancer, Pancreas Cancer, Pancreatic Diseases","enrollment":967},{"nctId":"NCT07096310","phase":"PHASE1, PHASE2","title":"Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-01-01","conditions":"Sepsis","enrollment":400},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT03671967","phase":"PHASE4","title":"PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2019-05-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":1084},{"nctId":"NCT05355350","phase":"PHASE4","title":"PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2022-07-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":""},{"nctId":"NCT07082465","phase":"","title":"Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand","status":"NOT_YET_RECRUITING","sponsor":"University of Oxford","startDate":"2025-08-01","conditions":"Drug Resistance, Bacterial, Bacteremia","enrollment":108000},{"nctId":"NCT06184659","phase":"PHASE4","title":"Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis","status":"RECRUITING","sponsor":"Scandinavian Critical Care Trials Group","startDate":"2025-06-26","conditions":"Sepsis, Septic Shock","enrollment":5800},{"nctId":"NCT04282785","phase":"","title":"Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2022-08-01","conditions":"Sepsis, Infection, Bacterial","enrollment":36},{"nctId":"NCT06977347","phase":"NA","title":"Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea","status":"NOT_YET_RECRUITING","sponsor":"CHOSEOK YOON","startDate":"2025-06-15","conditions":"Severe Community-acquired Pneumonia (sCAP)","enrollment":100},{"nctId":"NCT06977165","phase":"","title":"Investigating the Impact of Sepsis Phenotypes on Antibiotic Treatment in Patients With Severe Pneumonia and Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University of Manchester","startDate":"2025-09-01","conditions":"Respiration Disorders, Respiratory Failure, Sepsis","enrollment":119},{"nctId":"NCT06972537","phase":"NA","title":"A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia","status":"RECRUITING","sponsor":"Shandong University","startDate":"2024-07-24","conditions":"Pneumonia","enrollment":42},{"nctId":"NCT06342115","phase":"PHASE4","title":"Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens","status":"RECRUITING","sponsor":"Beneficência Portuguesa de São Paulo","startDate":"2025-03-26","conditions":"Febrile Neutropenia","enrollment":176},{"nctId":"NCT06929702","phase":"PHASE4","title":"Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-04-22","conditions":"Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem","enrollment":58},{"nctId":"NCT03583333","phase":"PHASE3","title":"Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-18","conditions":"Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia","enrollment":274},{"nctId":"NCT02820987","phase":"PHASE3","title":"PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-09-27","conditions":"Septic Shock","enrollment":119},{"nctId":"NCT06760143","phase":"","title":"Antibiotic Prophylaxis in Lung-Transplant Recipients","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2024-01-12","conditions":"Lung-transplant Recipients, Antibiotic Prophylaxis","enrollment":90},{"nctId":"NCT06749483","phase":"","title":"The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units?","status":"RECRUITING","sponsor":"Jena University Hospital","startDate":"2024-12-27","conditions":"Critical Illness, Intensive Care Unit Delirium, Neurocognitive Deficit","enrollment":100},{"nctId":"NCT03891433","phase":"PHASE4","title":"Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae","status":"SUSPENDED","sponsor":"Universidad del Norte","startDate":"2019-04-01","conditions":"Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria","enrollment":198},{"nctId":"NCT05971979","phase":"","title":"Therapeutic Drug Monitoring - Targeting IMproved Effectiveness","status":"COMPLETED","sponsor":"Manchester University NHS Foundation Trust","startDate":"2023-12-12","conditions":"Pneumonia, Sepsis, Infection, Bacterial","enrollment":30},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT04803422","phase":"NA","title":"Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2021-04-01","conditions":"Complicated Appendicitis","enrollment":3193},{"nctId":"NCT03467854","phase":"","title":"PK of Piperacillin/Tazobactam in Adults Undergoing ECMO","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-01-01","conditions":"Acute Respiratory Failure With Hypoxia","enrollment":2},{"nctId":"NCT05753735","phase":"PHASE2","title":"eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-01-18","conditions":"Pancreatic Fistula","enrollment":3},{"nctId":"NCT04436991","phase":"","title":"Antibiotic Dosing in Geriatric Patients At the Emergency Department","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2018-01-03","conditions":"Elderly Infection, Frailty, Frail Elderly Syndrome","enrollment":180},{"nctId":"NCT04276480","phase":"NA","title":"Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2022-02-16","conditions":"Enterobacteriaceae Infections","enrollment":9},{"nctId":"NCT05786495","phase":"NA","title":"Short Antibiotic Treatment in High Risk Febrile Neutropenia","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-10-01","conditions":"Febrile Neutropenia","enrollment":80},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06293677","phase":"PHASE4","title":"Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2024-03-01","conditions":"Febrile Neutropenia","enrollment":30},{"nctId":"NCT06026852","phase":"NA","title":"Validation of Betalactam ML Prediction Models - TDMAide","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2024-09-26","conditions":"Infections","enrollment":600},{"nctId":"NCT06422533","phase":"NA","title":"Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2023-11-07","conditions":"Hematologic Neoplasms, Neutropenia","enrollment":226},{"nctId":"NCT06338345","phase":"NA","title":"Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Grenoble","startDate":"2024-09-01","conditions":"Cardiogenic Shock, Post-cardiac Surgery, Cardiac Arrest","enrollment":225},{"nctId":"NCT03897582","phase":"","title":"Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study","status":"RECRUITING","sponsor":"Centre Hospitalier de Valenciennes","startDate":"2019-02-22","conditions":"Beta-lactam, Continuous Renal Replacement Therapy, Pneumonia","enrollment":65},{"nctId":"NCT03289351","phase":"PHASE4","title":"Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis","status":"COMPLETED","sponsor":"Phoenix Children's Hospital","startDate":"2017-05-22","conditions":"Perforated Appendicitis, Postoperative Infection","enrollment":162},{"nctId":"NCT05094154","phase":"PHASE4","title":"Effect of Antibiotic Choice On ReNal Outcomes (ACORN)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2021-11-10","conditions":"Sepsis, AKI, Neurotoxicity","enrollment":2634},{"nctId":"NCT04724044","phase":"PHASE3","title":"Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2021-01-25","conditions":"Community-acquired Pneumonia, Sepsis, Inflammatory Response","enrollment":278},{"nctId":"NCT05102162","phase":"PHASE4","title":"BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia","status":"TERMINATED","sponsor":"University of Florida","startDate":"2021-12-17","conditions":"Pneumonia","enrollment":35},{"nctId":"NCT03159754","phase":"PHASE4","title":"Optimal Care of Complicated Appendicitis","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-06-29","conditions":"Appendicitis, Perforated Appendicitis, Ruptured Appendicitis","enrollment":40},{"nctId":"NCT04033029","phase":"","title":"Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2021-01-01","conditions":"Hemodiafiltration, Sepsis, Acute Kidney Injury","enrollment":20},{"nctId":"NCT06076200","phase":"","title":"Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations","status":"RECRUITING","sponsor":"Shandong University","startDate":"2023-09-30","conditions":"Early-Onset Neonatal Sepsis","enrollment":50},{"nctId":"NCT03850860","phase":"","title":"Comparison of Two Empirical Antimicrobial Therapies of Prosthetic Joint Infection","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-12-01","conditions":"Bone and Joint Infection","enrollment":178},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT05981079","phase":"PHASE4","title":"Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2023-07-31","conditions":"Late-Onset Neonatal Sepsis","enrollment":332},{"nctId":"NCT05943223","phase":"PHASE2","title":"Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)","status":"UNKNOWN","sponsor":"McMaster Children's Hospital","startDate":"2024-01","conditions":"Appendicitis Perforated","enrollment":16},{"nctId":"NCT03262142","phase":"PHASE4","title":"Targeted AntiBiotics for Chronic Pulmonary Diseases","status":"TERMINATED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2018-01-10","conditions":"COPD, Respiratory Tract Infections, Pseudomonas Aeruginosa","enrollment":51},{"nctId":"NCT02437045","phase":"PHASE4","title":"Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2015-04","conditions":"Bloodstream Infections","enrollment":100},{"nctId":"NCT05565222","phase":"PHASE3","title":"Piperacillin-tazobactam and Temocillin as Carbapenem-alternatives for the Treatment of Severe Infections Due to Extended-spectrum Beta-lactamase-Producing Gram-negative Enterobacteriaceae in the Intensive Care Unit","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-03-11","conditions":"Sepsis, Septic Shock","enrollment":600},{"nctId":"NCT03108690","phase":"PHASE4","title":"Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia","status":"WITHDRAWN","sponsor":"Sara Thønnings","startDate":"2017-10-01","conditions":"Bacteremia","enrollment":""},{"nctId":"NCT04915872","phase":"","title":"Are Standard Dosing Regimens of Piperacillin-Tazobactam Suitable in Critically Ill Patients With Open Abdomen and Negative Pressure Wound Therapy? A Population Pharmacokinetic Study.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-01","conditions":"Laparotomy, Critical Illness, Piperacillin, Tazobactam Drug Combination","enrollment":46},{"nctId":"NCT04577989","phase":"","title":"Clinical Comparison of Treatment Strategies in AmpC Beta-lactamase Producing Enterobacterales in a Swiss Tertiary Care Hospital","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-12-14","conditions":"Infection With AmpC Beta-lactamase Producing Enterobacterales","enrollment":270},{"nctId":"NCT03748095","phase":"","title":"Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care","status":"UNKNOWN","sponsor":"University Hospital, Rouen","startDate":"2019-03-12","conditions":"Resuscitation Patients With Sepsis","enrollment":90},{"nctId":"NCT03909698","phase":"","title":"Antibiotic Dosing in Patients on Intermittent Hemodialysis","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2016-09-15","conditions":"Kidney Failure, Chronic, Antibiotics, Hemodialysis","enrollment":150},{"nctId":"NCT03990467","phase":"NA","title":"Observed Pharmacokinetic of Piperacillin/Tazobactam Compared to Amikacin in ICU","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2021-01-28","conditions":"Septic Shock, Sepsis, Sepsis Syndrome","enrollment":60},{"nctId":"NCT03985514","phase":"PHASE4","title":"Acute Appendicitis: Active Observation With and Without Antibiotics","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2018-05-15","conditions":"Appendicitis","enrollment":126},{"nctId":"NCT05349305","phase":"","title":"Population Pharmacokinetics of Lassila Tazobactam in Patients After Aortic Dissection","status":"UNKNOWN","sponsor":"The Second Hospital of Shandong University","startDate":"2022-04-30","conditions":"Aortic Dissection, Lung Infection","enrollment":50},{"nctId":"NCT04394182","phase":"NA","title":"Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","status":"SUSPENDED","sponsor":"Fundacion GenesisCare","startDate":"2020-04-21","conditions":"Pneumonia, Viral, Cytokine Storm","enrollment":15},{"nctId":"NCT03922451","phase":"","title":"Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2019-08-27","conditions":"Drug Effect","enrollment":4},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT04748120","phase":"NA","title":"Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2020-12-28","conditions":"Covid19, Appendicitis, Cholecystitis, Acute","enrollment":2},{"nctId":"NCT04042077","phase":"PHASE3","title":"Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections","status":"TERMINATED","sponsor":"Menarini Group","startDate":"2019-09-25","conditions":"Surgical Site Infection","enrollment":268},{"nctId":"NCT01694069","phase":"PHASE4","title":"Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":6},{"nctId":"NCT02991937","phase":"PHASE4","title":"Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2016-12","conditions":"Appendicitis","enrollment":39},{"nctId":"NCT02840136","phase":"NA","title":"LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"University Ghent","startDate":"2016-02","conditions":"Cystic Fibrosis","enrollment":40},{"nctId":"NCT05134298","phase":"","title":"Pharmacokinetics of Piperacillin and Meropenem in ICU Patients","status":"UNKNOWN","sponsor":"Karolinska University Hospital","startDate":"2019-11-01","conditions":"Antibiotic Pharmacokinetics","enrollment":50},{"nctId":"NCT05060419","phase":"PHASE2","title":"Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-10-08","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":150},{"nctId":"NCT03019965","phase":"NA","title":"Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2017-02-01","conditions":"Sepsis","enrollment":426},{"nctId":"NCT04132115","phase":"","title":"Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2019-10-01","conditions":"Therapeutic Drug Monitoring, Subarachnoid Hemorrhage, Intracerebral Hemorrhage","enrollment":104},{"nctId":"NCT04914039","phase":"","title":"Evaluation of CTA on the Assessment of Brain Death","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-02-01","conditions":"Brain Death","enrollment":63},{"nctId":"NCT04895657","phase":"PHASE4","title":"Extended-infusion of Piperacillin-Tazobactam Versus Intermittent Infusion","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-07-27","conditions":"Gram-Negative Infections","enrollment":56},{"nctId":"NCT04879030","phase":"PHASE2, PHASE3","title":"Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD","status":"COMPLETED","sponsor":"Haiphong University of Medicine and Pharmacy","startDate":"2020-01-01","conditions":"COPD Exacerbation Acute","enrollment":170},{"nctId":"NCT02242006","phase":"","title":"Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2014-10","conditions":"Critical Illness, Kidney Injury, Pharmacokinetics","enrollment":90},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04816968","phase":"PHASE1","title":"Antibiotics Continuous Infusion at Home","status":"UNKNOWN","sponsor":"Ospedale San Carlo Borromeo","startDate":"2021-09","conditions":"Severe Bacterial Infections","enrollment":50},{"nctId":"NCT03583749","phase":"","title":"Pharmacokinetics and Safety of Antimicrobial Agents Administered by Subcutaneous Route in Patients AGEd Over 65 Years","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2019-08-07","conditions":"Antimicrobials, Subcutaneous Injection, Antibiotic","enrollment":150},{"nctId":"NCT04233996","phase":"PHASE4","title":"Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2019-06-05","conditions":"Febrile Neutropenia","enrollment":150},{"nctId":"NCT03765645","phase":"NA","title":"Comparison of 9 Doses vs 3 Doses of Post Operative Antibiotics in Live Liver Donors","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2018-10-04","conditions":"Antibiotic Prophylaxis, Postoperative Infection","enrollment":126},{"nctId":"NCT02609646","phase":"","title":"AbioKin - Antibiotic Kinetics","status":"COMPLETED","sponsor":"Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva","startDate":"2016-01","conditions":"Critical Illness, Infection","enrollment":1500},{"nctId":"NCT03560232","phase":"PHASE4","title":"Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens","status":"TERMINATED","sponsor":"Mercy Health Ohio","startDate":"2018-07-09","conditions":"Open Fracture, Post-Op Wound Infection","enrollment":17},{"nctId":"NCT01793012","phase":"","title":"Drug Monitoring of Antibiotics in Critical Care Patients","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2013-03","conditions":"ARDS, Sepsis","enrollment":186}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["piperacillin-tazobactam","Zosyn"],"phase":"marketed","status":"active","brandName":"Piperacillin, Tazobactam Drug Combination","genericName":"Piperacillin, Tazobactam Drug Combination","companyName":"Phoenix Children's Hospital","companyId":"phoenix-children-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piperacillin inhibits bacterial cell wall synthesis while tazobactam inhibits beta-lactamase enzymes, allowing piperacillin to kill a broader spectrum of bacteria including beta-lactamase-producing organisms. Used for Bacterial infections in pediatric patients (including intra-abdominal, skin and soft tissue, and respiratory tract infections), Febrile neutropenia in pediatric cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}